Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US begins trials for artificial blood in heart surgery:

This article was originally published in Clinica

Executive Summary

Canadian company Hemosol is to begin Phase II clinical trials in the US of its oxygen-carrying artificial blood, Hemolink, in patients undergoing coronary artery bypass grafting surgery (CABG). Researchers will examine whether using Hemolink as a red blood cell substitute during CABG will lessen some of the adverse effects associated with the bypass procedure, such as bleeding disorders and blood pressure instability. Phase II trials of Hemolink in patients undergoing CABG are already underway in the UK and Canada. Toronto-based Hemosol is one of several companies developing blood substitutes (see Clinica No 812, p 14).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel